Launch of Ipsen's Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone- dependent prostate cancer
Paris/Lausanne (ots) - Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss- based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce ...
mehr